This Phase II study evaluates a novel preparative regimen of treosulfan, fludarabine, and low-dose TBI for pediatric patients with AML and MDS undergoing allogeneic hematopoietic cell transplantation. The primary objective is to achieve overall survival rates comparable to conventional myeloablative regimens while minimizing toxicity. Given the high unmet need in pediatric oncology, particularly in hematological malignancies, successful outcomes could position this regimen favorably in the market, potentially leading to broader adoption in clinical practice. The collaboration with established institutions and organizations, such as the Center for International Blood and Marrow Transplant Research and National Marrow Donor Program, enhances credibility and may facilitate future partnerships or licensing opportunities. However, competitive analysis indicates that other preparative regimens are also in development, necessitating ongoing diligence to assess market positioning and differentiation.